MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation

被引:138
作者
Chadee, DN
Kyriakis, JM
机构
[1] Tufts Univ New England Med Ctr, Dept Med, Mol Cardiol Res Inst, Boston, MA 02111 USA
[2] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
关键词
D O I
10.1038/ncb1152
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ERK group of mitogen-activated protein kinases (MAPKs) is essential for cell proliferation stimulated by mitogens, oncogenic ras and raf (ref. 1). All MAPKs are activated by MAP3K/MEK/MAPK core pathways(1) and the Raf protooncoproteins, especially B-Raf, are ERK-specific MAP3Ks (refs 1-3). Mixed lineage kinase-3 (MLK3) is a MAP3K that was thought to be a cytokine-activated, and comparatively selective, regulator of the JNK group of MAPKs (refs 1, 4-6). Here we report that silencing of mlk3 by RNAi suppressed mitogen and cytokine activation not only of JNK but of ERK and p38 as well. Silencing mlk3 also blocked mitogen-stimulated phosphorylation of B-Raf at Thr 598 and Ser 601, a step required for B-Raf activation(7,8). Furthermore, silencing mlk3 prevented serum-stimulated cell proliferation and the proliferation of tumour cells bearing either oncogenic Ki-Ras or loss-of-function neurofibromatosis-1 (NF1) or NF2 mutations. The proliferation of tumour cells containing activating B-raf or raf-1 mutations was unaffected by silencing mlk3. Our results define an unexpected role for MLK3 in mitogen regulation of B-Raf, ERK and cell proliferation.
引用
收藏
页码:770 / 776
页数:7
相关论文
共 30 条
[1]   Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells [J].
Balmanno, K ;
Cook, SJ .
ONCOGENE, 1999, 18 (20) :3085-3097
[2]   Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry [J].
Brunet, A ;
Roux, D ;
Lenormand, P ;
Dowd, S ;
Keyse, S ;
Pouysségur, J .
EMBO JOURNAL, 1999, 18 (03) :664-674
[3]   Genomewide view of gene silencing by small interfering RNAs [J].
Chi, JT ;
Chang, HY ;
Wang, NN ;
Chang, DS ;
Dunphy, N ;
Brown, PO .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (11) :6343-6346
[4]   Positive and negative regulation of Raf kinase activity and function by phosphorylation [J].
Chong, H ;
Lee, J ;
Guan, KL .
EMBO JOURNAL, 2001, 20 (14) :3716-3727
[5]   NF1 tumor suppressor gene function: Narrowing the GAP [J].
Cichowski, K ;
Jacks, T .
CELL, 2001, 104 (04) :593-604
[6]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[7]   Targeting ras signalling pathways in cancer therapy [J].
Downward, J .
NATURE REVIEWS CANCER, 2003, 3 (01) :11-22
[8]   TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway [J].
Dumitru, CD ;
Ceci, JD ;
Tsatsanis, C ;
Kontoyiannis, D ;
Stamatakis, K ;
Lin, JH ;
Patriotis, C ;
Jenkins, NA ;
Copeland, NG ;
Kollias, G ;
Tsichlis, PN .
CELL, 2000, 103 (07) :1071-1083
[9]   Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells [J].
Elbashir, SM ;
Harborth, J ;
Lendeckel, W ;
Yalcin, A ;
Weber, K ;
Tuschl, T .
NATURE, 2001, 411 (6836) :494-498
[10]   Mixed-lineage kinase control of JNK and p38 MAPK pathways [J].
Gallo, KA ;
Johnson, GL .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (09) :663-672